The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Open accessAbstract
Parkinson's disease (PD) is a chronic and progressive disorder characterized neuropathologically by loss of dopamine neurons in the substantia nigra, intracellular proteinaceous inclusions, reduction of dopaminergic terminals in the striatum, and increased neuroinflammatory cells. The consequent reduction of dopamine in the basal ganglia results in the classical parkinsonian motor phenotype. A growing body of evidence suggest that neuroinflammation mediated by microglia, the resident macrophage-like immune cells in the brain, play a contributory role in PD pathogenesis. Microglia participate in both physiological and pathological conditions. In the former, microglia restore the integrity of the central nervous system and, in the latter, they promote disease progression. Microglia acquire different activation states to modulate these cellular functions. Upon activation to the M1 phenotype, microglia elaborate pro-inflammatory cytokines and neurotoxic molecules promoting inflammation and cytotoxic responses. In contrast, when adopting the M2 phenotype microglia secrete anti-inflammatory gene products and trophic factors that promote repair, regeneration, and restore homeostasis. Relatively little is known about the different microglial activation states in PD and a better understanding is essential for developing putative neuroprotective agents. Targeting microglial activation states by suppressing their deleterious pro-inflammatory neurotoxicity and/or simultaneously enhancing their beneficial anti-inflammatory protective functions appear as a valid therapeutic approach for PD treatment. In this review, we summarize microglial functions and, their dual neurotoxic and neuroprotective role in PD. We also review molecules that modulate microglial activation states as a therapeutic option for PD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–208 of 208
Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease
Świątkiewicz, M., Zaremba, M., Joniec‐Maciejak, I., Członkowski, A., & Kurkowska‐Jastrzębska, I. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71480-4 · Cited by 52
Joniec‐Maciejak, I., Ciesielska, A., Wawer, A., Sznejder-Pachołek, A., Schwenkgrub, J., Cudna, A., Hadaczek, P., Bankiewicz, K. S., Członkowska, A., & Członkowski, A. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.03.008 · Cited by 43
Schwenkgrub, J., Joniec‐Maciejak, I., Sznejder-Pachołek, A., Wawer, A., Ciesielska, A., Bankiewicz, K. S., Członkowska, A., & Członkowski, A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)70962-9 · Cited by 35
Parkinson’s disease-associated DJ-1 modulates innate immunity signaling in Caenorhabditis elegans
Castro, E. M. C., Waak, J., Weber, S. S., Fiesel, F. C., Oberhettinger, P., Schütz, M., Autenrieth, I. B., Springer, W., & Kahle, P. J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0397-4 · Cited by 35
Taming of macrophage and microglial cell activation by microRNA-124
Conrad, A., & Dittel, B. N. (2011) · Cell Research · doi:10.1038/cr.2011.9 · Cited by 30
The future of JAK inhibition in myelofibrosis and beyond
Mascarenhas, J. O., Cross, N. C. P., & Mesa, R. A. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.06.002 · Cited by 30
Therapeutic strategies for neurodegenerative disorders: Emerging clues from parkinson's disease
Bjarkam, C. R., & Sørensen, J. C. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.025 · Cited by 25
Nicht-steroidale Analgetika haben keinen protektiven Effekt gegen M. Parkinson
Steurer, J. (2011) · Praxis · doi:10.1024/1661-8157/a000535 · Cited by 3
Cited by
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Huang, X., Hussain, B., & Chang, J. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13569 · Cited by 709
Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets
Tschoe, C., Bushnell, C. D., Duncan, P. W., Alexander-Miller, M. A., & Wolfe, S. Q. (2020) · Journal of Stroke · doi:10.5853/jos.2019.02236 · Cited by 490
Ronaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Metadata
- Authors
- Subramaniam, S. R., & Federoff, H. J.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-06-08
- Volume
- 9
- Pages
- 176-176
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2621426836
- Cited by
- 347
- References
- 208
- FWCI
- 14.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.